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A systematic review to be published in the São Paulo Medi-
cal Journal/Evidence for Health Care in January 2009, prepared 
by teams at the Brazilian Cochrane Center and the Depart-
ment of Ophthalmology of Universidade Federal de São Paulo 
(Unifesp), shows that the use of bevacizumab in intraocular 
injections increases the effi cacy of the current treatment for 
macular degeneration. In relation to photodynamic therapy, 
the costs due to medications fall by around 99%. 
Taking the prevalence data from the United States,1 we 
estimate that there are at least fi ve million cases in Brazil. 
Thus, with the decrease in costs from around 10,000 dollars 
per patient to 33 dollars per patient with the new treatment, 
the potential budgetary impact could be a reduction from 50 
billion to 175 million dollars in Brazil alone!
This is just one of the examples that serve to explain several 
things: the fi rst is that, even with expenditure of two trillion 
dollars per year, the American healthcare system is unsustainable 
and leaves millions of people without healthcare coverage. For 
further information, watch Michael Moore’s fi lm “Sicko”, which 
is a must for the medical profession. Secondly, it explains why 
medical fees in Brazil are getting smaller all the time, since there 
is always a great chance that the funds will go into new technolo-
gies, although in most cases, the effectiveness of such technologies 
remains unconfi rmed by good-quality evidence.
A large proportion of the maintenance of quality and 
extensive inclusion of the population within the Brazilian 
healthcare systems, both public and private, is achieved at 
the cost of reduced payments to healthcare professionals. 
However, as we have been saying here for many years, there is 
a new path that can be taken: that of the search for effi cacy, 
effectiveness, effi ciency and safety, based on clinical research 
that is adequately designed and conducted in order to constitute 
good evidence.
Designing such clinical research is not a great problem, 
although only a small number of people interested in clinical 
research in fact have the preparation to do this. The greater 
diffi culty lies in obtaining fi nance from funding agencies to 
conduct such studies. In our view, they lack a body of review-
ers who are suffi ciently technically prepared for this and, with 
honorable exceptions, their reports are often a muddle between 
absence of knowledge and the verge of utter cynicism. Just 
to cite two of them: one classifi ed the Cochrane reviews as 
unrelated to postgraduate activities (as if mapping out present 
knowledge to establish its relevance and better defi ne new 
research did not form part of the search for new knowledge!) 
and the other took the view that those who publish a lot must 
have a lot of funds and so would not need fi nancial support! 
Despite such problems, the number of papers published from 
Brazilian studies has increased tremendously; in other words, 
while we have improved our scientifi c production, there is still 
a lack of knowledge about how to apply this.
It is worth bearing in mind that the Medical Research 
Council (MRC) of the United Kingdom considers it unethical 
to carry out redundant research on matters for which answers 
already exist, or researches that are outside of the context, or 
for which the methodology produces unreliable results. The 
MRC requires systematic reviews to map out the current 
knowledge that was acquired with adequate methodology, 
so that research projects can then be designed with questions 
posed and outcomes defi ned in such a way as to diminish the 
doubts regarding the subject. These doubts generally relate to 
the effi cacy, effectiveness, effi ciency and safety of the approaches 
that will be taken sooner or later, to the benefi t of science and 
medical practice.2,3 
It is no coincidence that the British Medical Journal (BMJ) 
considers that evidence-based medicine (EBM) is one of the 
15 best ideas within medicine to have arisen since 1840. The 
Cochrane Library is indexed in the Institute for Scientifi c 
Information (ISI) and has an impact factor of 4.68. It is the 
14th most cited source within clinical medicine. The São Paulo 
Medical Journal/Evidence for Health Care was invited to 
become a member of the Web of Science (ISI) because of its 
number of citations and is now being monitored more closely 
by that organization.
The search for evidence to assess new health technology 
requires not only the availability of expertise but also impar-
tiality. For this, it is fundamental that there should be funding 
agencies with suffi cient preparation and impartiality to play a 
supporting role. In this way, the major confl icts of interest that 
occur naturally when parties interested in creating, producing 
and selling fund clinical research into their own products can 
be avoided. Even when carried out with the greatest rigor, in-
dustry-funded research does not attain the necessary credibility, 
because of the suspicion of confl icts of interest. Fortunately, in 
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Brazil, the Ministry of Health has been taking 
an increasingly determined and authoritative 
role in this respect, as has also been occurring 
in the United Kingdom, Canada, Australia 
and the United States, through their research 
quality and health policy agencies. 
We take the view that it is also time for 
there to be a major research agency of world-
wide nature, which would bring together 
funds for an international consortium for as-
sessments that are impartial and independent 
of conflicts of interest. This would have the 
purpose of assessing new technologies using 
funds from producers and the governments 
of different countries, in order to study areas 
of human interest and, in particular, to meet 
the needs of the poorer countries, whose im-
portant issues are systematically neglected.
An article prepared following a symposium 
of American health economists and published 
by professors at the Wharton Business School, 
in 2003,4 has already predicted economic 
chaos in healthcare before 2011. It suggested 
that preventive medicine and the principles of 
EBM should be applied as a the strategy for 
economic and healthcare survival, in order to 
face up to costs that, at that time, were pro-
jected to reach 2.7 billion dollars in 2011, in 
the United States. 
Two articles published recently in the 
Journal of the American Medical Association 
(JAMA), the medical journal currently with 
the highest impact factor, in May5 and Octo-
ber6 2008, go along the same lines. The article 
“The ‘3T’s’ road map to transform US health 
care”, by Dougherty and Conway,5 discusses 
the way forward to reach a new situation for 
American healthcare, namely:
- First, the process of innovation needs to 
be accelerated, i.e. the efficiency of new 
health technology assessments needs to 
be increased, instead of having to wait for 
them at the snail’s pace of today. For this, 
phase I, II and III clinical trials need to 
be performed rapidly and efficiently;
- Second, evidence-based decision-making 
needs to be implemented, with regard to 
both the prevention and the diagnosis 
and therapy of diseases (topics that can 
be presumed to have some relationship 
with science);
- Third, the impact of the new (and old) 
technologies applied needs to be continu-
ously measured (to obtain evidence).
If anyone has any doubts about the ways 
to face up to the present world crises in the 
economy and in healthcare, it seems that 
opening one’s eyes impartially is already a 
good start. It is good to note that the medi-
cal schools of York, in the United Kingdom, 
and McMaster, in Canada, have managed in 
40 years, through innovations in teaching, 
learning and EBM, to largely reach the level 
of Oxford and Cambridge, with their ap-
proximately 800 years of history.
It should be noted that the one or two 
trillion dollars with which it is planned to face 
up to the present world economic crisis could 
have been saved over the last two or three years, 
if they had not been wasted on approaches 
without scientific proof of their effectiveness 
and safety within many fields: not just within 
medicine but within all human activities. We 
hope that this current economic crisis will 
enable science and technology to make this 
the century of efficiency, safety and quality 
of life, within a healthy environment. More 
lives will be saved, less suffering (morbidity) 
will occur and the gain in human health will 
be detectable in terms of better quality of life 
and social behavior. Since global warming 
is associated with waste of resources, even 
nature will benefit! The treatment for macular 
degeneration may preserve or improve visual 
acuity, but only learning the use of reason will 
improve the decision-making process.
Education relating to the principles of 
EBM for everyone is the inexorable path to fol-
low, for ordinary citizens, health professionals, 
lawyers, journalists, health economists, teach-
ers and politicians. The path may be stony, 
but even Paramecium sp has a plan B when 
faced with obstacles. It should, incidentally, 
be noted that having a plan B is one of the 
signs used to demonstrate intelligence in the 
animal kingdom. It is time to accept a change 
in direction. Could it be that Paramecium sp is 
intelligent? It seems to have a plan B.
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